Years of research in the academic setting led scientific founders Shen Yu and Fred Ausubel to observe that rapidly proliferating cells exhibit drastically different phenotypes depending on available nutrients and carbon sources. Most whole-cell screening methods make use of culture conditions optimized for robust growth, which may not be relevant to disease
state. Through careful study of central metabolic processes in bacteria, Octagon has developed a discovery platform that identifies metabolic processes that drive proliferative disease and ranks these potential drug targets using computational models of metabolic networks.
This platform has identified novel therapeutic targets and small molecule inhibitors that are invisible in standard culture conditions. Octagon has applied these insights to the development of novel medicines for autoimmune disorders and infectious disease. Octagon’s discovery platform is being applied to additional promising compound libraries through collaboration with industry and academia. Contact us here to learn more about discovery partnership opportunities.